AAAAAA

   
Results: 1-10 |
Results: 10
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes
Authors: Stoll, SW Kansra, S Peshick, S Fry, DW Leopold, WR Wiesen, JF Sibilia, M Zhang, T Werb, Z Derynck, R Wagner, EF Elder, JT
Citation: Sw. Stoll et al., Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes, NEOPLASIA, 3(4), 2001, pp. 339-350
Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6
Authors: Fry, DW Bedford, DC Harvey, PH Fritsch, A Keller, PR Wu, ZP Dobrusin, E Leopold, WR Fattaey, A Garrett, MD
Citation: Dw. Fry et al., Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6, J BIOL CHEM, 276(20), 2001, pp. 16617-16623
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator
Authors: Wang, YL Li, J Booher, RN Kraker, A Lawrence, T Leopold, WR Sun, Y
Citation: Yl. Wang et al., Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator, CANCER RES, 61(22), 2001, pp. 8211-8217
Histidylbenzylglycinamides - A novel class of farnesyl diphosphate-competitive peptidic farnesyltransferase inhibitors
Authors: Sebolt-Leopold, JS Leonard, DM Leopold, WR
Citation: Js. Sebolt-leopold et al., Histidylbenzylglycinamides - A novel class of farnesyl diphosphate-competitive peptidic farnesyltransferase inhibitors, CANC DRUG, 8, 2001, pp. 103-114
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
Authors: Vincent, PW Bridges, AJ Dykes, DJ Fry, DW Leopold, WR Patmore, SJ Roberts, BJ Rose, S Sherwood, V Zhou, HR Elliott, WL
Citation: Pw. Vincent et al., Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts, CANC CHEMOT, 45(3), 2000, pp. 231-238
3-(3,5-dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase
Authors: Thompson, AM Connolly, CJC Hamby, JM Boushelle, S Hartl, BG Amar, AM Kraker, AJ Driscoll, DL Steinkampf, RW Patmore, SJ Vincent, PW Roberts, BJ Elliott, WL Klohs, W Leopold, WR Showalter, HDH Denny, WA
Citation: Am. Thompson et al., 3-(3,5-dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase, J MED CHEM, 43(22), 2000, pp. 4200-4211
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Authors: Sebolt-Leopold, JS Dudley, DT Herrera, R Van Becelaere, K Wiland, A Gowan, RC Tecle, H Barrett, SD Bridges, A Przybranowski, S Leopold, WR Saltiel, AR
Citation: Js. Sebolt-leopold et al., Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, NAT MED, 5(7), 1999, pp. 810-816
Regulation of metastasis-related gene expression by p53: A potential clinical implication
Authors: Sun, Y Wicha, M Leopold, WR
Citation: Y. Sun et al., Regulation of metastasis-related gene expression by p53: A potential clinical implication, MOL CARCINO, 24(1), 1999, pp. 25-28
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors
Authors: Sun, Y Fry, DW Vincent, P Nelson, JM Elliott, W Leopold, WR
Citation: Y. Sun et al., Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors, ANTICANC R, 19(2A), 1999, pp. 919-924
Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
Authors: Smaill, JB Palmer, BD Rewcastle, GW Denny, WA McNamara, DJ Dobrusin, EM Bridges, AJ Zhou, HR Showalter, HDH Winters, RT Leopold, WR Fry, DW Nelson, JM Slintak, V Elliot, WL Roberts, BJ Vincent, PW Patmore, SJ
Citation: Jb. Smaill et al., Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor, J MED CHEM, 42(10), 1999, pp. 1803-1815
Risultati: 1-10 |